SOLANA BEACH, CA, USA I June 05, 2025 I Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 (https://bpsasm.org/) that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain.
Professor Saoirse O’Sullivan, Vice President of Translation Sciences at Artelo Biosciences, presented results from an animal study titled: “The Fatty Acid Binding Protein 5 Inhibitor ART26.12 is a Novel Analgesic for Osteoarthritis Pain.” The data builds upon an extensive set of pre-clinical data for ART26.12 that demonstrates analgesic and anti-nocicpetive effects in multiple models of pain.
Positive effects of ART26.12 were observed in a surgical rat model of osteoarthritis, in which either single or repeated oral doses of Artelo’s FABP5 inbitor increased the ability of rats to bear weight on the limb with OA out to four weeks.
Professor O’Sullivan stated, “ART26.12 was effective in a dose-responsive manner, with sustained and consistent effects over 28 days. The analgesic effect of ART26.12 was similar to naproxen, a proven first-line therapy which is often hampered by a number of serious side effects when taken chronically.”
Now undergoing human trials, ART26.12 is a novel, non-opioid, non-steroidal drug candidate initially in development for the prevention and treatment of peripheral neuropathy caused by common chemotherapy treatments with potential for development as an alternative for chronic OA pain.
OA is a progressive joint disease in which cartilage wears away over time, causing chronic pain, stiffness, swelling, and significant loss of mobility, especially in the knees, hips, hands, and spine. It affects approximately 606.9 million people globally, including over 32 million in the U.S., and can lead to disabling pain, reduced quality of life, and loss of independence, especially in advanced cases.
About ART26.12
ART26.12, Artelo’s lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Data from the first Phase 1 trial with ART26.12 is anticipated in Q2 2025. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and X: @ArteloBio.
SOURCE: Artelo Biosciences
Post Views: 786
SOLANA BEACH, CA, USA I June 05, 2025 I Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 (https://bpsasm.org/) that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain.
Professor Saoirse O’Sullivan, Vice President of Translation Sciences at Artelo Biosciences, presented results from an animal study titled: “The Fatty Acid Binding Protein 5 Inhibitor ART26.12 is a Novel Analgesic for Osteoarthritis Pain.” The data builds upon an extensive set of pre-clinical data for ART26.12 that demonstrates analgesic and anti-nocicpetive effects in multiple models of pain.
Positive effects of ART26.12 were observed in a surgical rat model of osteoarthritis, in which either single or repeated oral doses of Artelo’s FABP5 inbitor increased the ability of rats to bear weight on the limb with OA out to four weeks.
Professor O’Sullivan stated, “ART26.12 was effective in a dose-responsive manner, with sustained and consistent effects over 28 days. The analgesic effect of ART26.12 was similar to naproxen, a proven first-line therapy which is often hampered by a number of serious side effects when taken chronically.”
Now undergoing human trials, ART26.12 is a novel, non-opioid, non-steroidal drug candidate initially in development for the prevention and treatment of peripheral neuropathy caused by common chemotherapy treatments with potential for development as an alternative for chronic OA pain.
OA is a progressive joint disease in which cartilage wears away over time, causing chronic pain, stiffness, swelling, and significant loss of mobility, especially in the knees, hips, hands, and spine. It affects approximately 606.9 million people globally, including over 32 million in the U.S., and can lead to disabling pain, reduced quality of life, and loss of independence, especially in advanced cases.
About ART26.12
ART26.12, Artelo’s lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Data from the first Phase 1 trial with ART26.12 is anticipated in Q2 2025. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and X: @ArteloBio.
SOURCE: Artelo Biosciences
Post Views: 786
